{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T02:53:47Z","timestamp":1792119227492,"version":"4.4.0"},"reference-count":62,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2009,2,1]],"date-time":"2009-02-01T00:00:00Z","timestamp":1233446400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2009,2,1]],"date-time":"2009-02-01T00:00:00Z","timestamp":1233446400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2009,2,1]],"date-time":"2009-02-01T00:00:00Z","timestamp":1233446400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2009,2,1]],"date-time":"2009-02-01T00:00:00Z","timestamp":1233446400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2009,2,1]],"date-time":"2009-02-01T00:00:00Z","timestamp":1233446400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2009,2,1]],"date-time":"2009-02-01T00:00:00Z","timestamp":1233446400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2009,2,1]],"date-time":"2009-02-01T00:00:00Z","timestamp":1233446400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000097","name":"National Center for Research Resources","doi-asserted-by":"publisher","award":["UL1RR024143"],"award-info":[{"award-number":["UL1RR024143"]}],"id":[{"id":"10.13039\/100000097","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmn.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Pharmacology"],"published-print":{"date-parts":[[2009,2]]},"DOI":"10.1016\/j.coph.2008.12.016","type":"journal-article","created":{"date-parts":[[2009,1,19]],"date-time":"2009-01-19T04:30:35Z","timestamp":1232339435000},"page":"74-80","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":41,"title":["Opiate and cocaine addiction: from bench to clinic and back to the bench"],"prefix":"10.1016","volume":"9","author":[{"given":"Mary Jeanne","family":"Kreek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo R","family":"Butelman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orna","family":"Levran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.coph.2008.12.016_bib1","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1038\/nrd897","article-title":"Pharmacotherapy of addictions","volume":"1","author":"Kreek","year":"2002","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.coph.2008.12.016_bib2","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1001\/archinte.1966.00290160004002","article-title":"Narcotic blockade","volume":"118","author":"Dole","year":"1966","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.coph.2008.12.016_bib3","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1001\/jama.1973.03220060039009","article-title":"Medical safety and side effects of methadone in tolerant individuals","volume":"223","author":"Kreek","year":"1973","journal-title":"JAMA"},{"key":"10.1016\/j.coph.2008.12.016_bib4","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1300\/J069v18n04_06","article-title":"Cocaine abuse sharply reduced in an effective methadone maintenance program","volume":"18","author":"Borg","year":"1999","journal-title":"J Addict Dis"},{"key":"10.1016\/j.coph.2008.12.016_bib5","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1300\/J069v25n01_07","article-title":"High methadone dose significantly reduces cocaine use in methadone maintenance treatment (MMT) patients","volume":"25","author":"Peles","year":"2006","journal-title":"J Addict Dis"},{"key":"10.1016\/j.coph.2008.12.016_bib6","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1016\/j.biopsych.2005.02.026","article-title":"Imaging brain mu-opioid receptors in abstinent cocaine users: time course and relation to cocaine craving","volume":"57","author":"Gorelick","year":"2005","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.coph.2008.12.016_bib7","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1097\/00001756-199408150-00018","article-title":"Repeated cocaine administration upregulates kappa and mu, but not delta, opioid receptors","volume":"5","author":"Unterwald","year":"1994","journal-title":"Neuroreport"},{"key":"10.1016\/j.coph.2008.12.016_bib8","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S0361-9230(98)00155-5","article-title":"Acute \u201cbinge\u201d cocaine increases mu-opioid receptor mRNA levels in areas of the rat mesolimbic mesocortical dopamine system","volume":"48","author":"Yuferov","year":"1999","journal-title":"Brain Res Bull"},{"key":"10.1016\/j.coph.2008.12.016_bib9","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0014-2999(96)00672-3","article-title":"Steady-state methadone in rats does not change mRNA levels of corticotropin-releasing factor, its pituitary receptor or pro-opiomelanocortin","volume":"315","author":"Zhou","year":"1996","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.coph.2008.12.016_bib10_1","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1038\/sj.npp.1300927","article-title":"Effects of high dose methadone maintenance on cocaine place conditioning, cocaine self-administration, and mu-opioid receptor mRNA expression in the rat brain","volume":"31","author":"Leri","year":"2006","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.coph.2008.12.016_bib11_1","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.neuroscience.2008.09.039","article-title":"Mu opioid receptor knockdown in the substantia nigra\/ventral tegmental area by synthetic small interfering RNA blocks the rewarding and locomotor effects of heroin","volume":"158","author":"Zhang","year":"2009","journal-title":"Neuroscience"},{"key":"10.1016\/j.coph.2008.12.016_bib12","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1677\/joe.1.06960","article-title":"Mu opioid receptor and orexin\/hypocretin mRNA levels in the lateral hypothalamus and striatum are enhanced by morphine withdrawal","volume":"191","author":"Zhou","year":"2006","journal-title":"J Endocrinol"},{"key":"10.1016\/j.coph.2008.12.016_bib13","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/nature04071","article-title":"A role for lateral hypothalamic orexin neurons in reward seeking","volume":"437","author":"Harris","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.coph.2008.12.016_bib14","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1016\/j.neuroscience.2008.03.023","article-title":"Effect of cocaine place conditioning, chronic escalating-dose binge pattern cocaine and its acute withdrawal on orexin\/hypocretin and preprodynorphin gene expressions in lateral hypothalamus of Fischer 344 and Sprague\u2013Dawley rats","volume":"153","author":"Zhou","year":"2008","journal-title":"Neuroscience"},{"key":"10.1016\/j.coph.2008.12.016_bib15_1","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1001\/archpsyc.63.3.324","article-title":"Stress-induced cocaine craving and hypothalamic-pituitary-adrenal responses are predictive of cocaine relapse outcomes","volume":"63","author":"Sinha","year":"2006","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.coph.2008.12.016_bib16","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s002130100919","article-title":"Naltrexone decreases craving and alcohol self-administration in alcohol dependent subjects and activates the hypothalamo-pituitary-adrenocortical axis","volume":"160","author":"O\u2019Malley","year":"2004","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.coph.2008.12.016_bib17","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S0022-3565(25)20974-0","article-title":"Corticotropin-releasing factor and type 1 corticotropin-releasing factor receptor messenger RNAs in rat brain and pituitary during \u201cbinge\u201d-pattern cocaine administration and chronic withdrawal","volume":"279","author":"Zhou","year":"1996","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.coph.2008.12.016_bib18_1","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1176\/appi.ajp.2007.05030503","article-title":"Stress, dysregulation of drug reward pathways, and the transition to drug dependence","volume":"164","author":"Koob","year":"2007","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.coph.2008.12.016_bib19","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1016\/j.neuroscience.2005.05.032","article-title":"Amygdalar vasopressin mRNA increases in acute cocaine withdrawal: evidence for opioid receptor modulation","volume":"134","author":"Zhou","year":"2005","journal-title":"Neuroscience"},{"key":"10.1016\/j.coph.2008.12.016_bib20_1","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/sj.npp.1301419","article-title":"Involvement of arginine vasopressin and V1b receptor in heroin withdrawal and heroin seeking precipitated by stress and by heroin","volume":"33","author":"Zhou","year":"2008","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.coph.2008.12.016_bib21","doi-asserted-by":"crossref","first-page":"5274","DOI":"10.1073\/pnas.85.14.5274","article-title":"Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats","volume":"85","author":"Di Chiara","year":"1988","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.coph.2008.12.016_bib22","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1007\/s00213-003-1688-3","article-title":"Effects of the endogenous kappa opioid agonist dynorphin A(1\u201317) on cocaine-evoked increases in striatal dopamine levels and cocaine-induced place preference in C57BL\/6J mice","volume":"172","author":"Zhang","year":"2004","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.coph.2008.12.016_bib23","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S0022-3565(24)29312-5","article-title":"Enadoline and butorphanol: evaluation of kappa-agonists on cocaine pharmacodynamics and cocaine self-administration in humans","volume":"299","author":"Walsh","year":"2001","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.coph.2008.12.016_bib24","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1038\/sj.npp.1300811","article-title":"Nalmefene induced elevation in serum prolactin in normal human volunteers: partial kappa-opioid agonist activity?","volume":"30","author":"Bart","year":"2005","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.coph.2008.12.016_bib25","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1007\/s00213-005-0167-4","article-title":"Differential effects of the novel kappa-opioid receptor antagonist, JDTic, on reinstatement of cocaine-seeking induced by footshock stressors vs. cocaine primes and its antidepressant-like effects in rats","volume":"183","author":"Beardsley","year":"2005","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.coph.2008.12.016_bib26","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1086\/324467","article-title":"Polysubstance abuse-vulnerability genes: genome scans for association, using 1,004 subjects and 1,494 single-nucleotide polymorphisms","volume":"69","author":"Uhl","year":"2001","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.coph.2008.12.016_bib27","doi-asserted-by":"crossref","first-page":"11864","DOI":"10.1073\/pnas.0500329102","article-title":"Pooled association genome scanning: validation and use to identify addiction vulnerability loci in two samples","volume":"102","author":"Liu","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.coph.2008.12.016_bib28","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1002\/ajmg.b.30436","article-title":"Addiction molecular genetics: 639,401 SNP whole genome association identifies many \u201ccell adhesion\u201d genes","volume":"141B","author":"Liu","year":"2006","journal-title":"Am J Med Genet B Neuropsychiatr Genet"},{"key":"10.1016\/j.coph.2008.12.016_bib29_1","doi-asserted-by":"crossref","first-page":"4170","DOI":"10.1038\/sj.mp.4002147","article-title":"Genotype patterns that contribute to increased risk for or protection from developing heroin addiction","volume":"13","author":"Nielsen","year":"2008","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.coph.2008.12.016_bib30_1","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1111\/j.1601-183X.2008.00410.x","article-title":"Genetic susceptibility to heroin addiction; a candidate\u2013gene association study","volume":"7","author":"Levran","year":"2008","journal-title":"Genes Brain Behav"},{"key":"10.1016\/j.coph.2008.12.016_bib31_1","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1093\/hmg\/ddn122","article-title":"ABCB1 (MDR1) genetic variants are associated with methadone doses required for effective treatment of heroin dependence","volume":"17","author":"Levran","year":"2008","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.coph.2008.12.016_bib32_1","doi-asserted-by":"crossref","unstructured":"Yuferov Y, Ji F, Nielsen DA, Levran O, Ho A, Morgello S, Shi R, Ott J, Kreek MJ: A functional haplotype implicated in vulnerability to develop cocaine dependence is associated with reduced PDYN expression in human brain. Neuropsychopharmacology 2008. Oct 15 [Epub ahead of print].","DOI":"10.1038\/npp.2008.187"},{"key":"10.1016\/j.coph.2008.12.016_bib33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1124\/pr.57.1.1","article-title":"Pharmacogenetics and human molecular genetics of opiate and cocaine addictions and their treatments","volume":"57","author":"Kreek","year":"2005","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.coph.2008.12.016_bib34","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0169-328X(03)00139-6","article-title":"Increased CRH mRNA levels in the rat amygdala during acute withdrawal from chronic \u201cbinge\u201d cocaine","volume":"114","author":"Zhou","year":"2003","journal-title":"Brain Res Mol Brain Res"},{"key":"10.1016\/j.coph.2008.12.016_bib35","doi-asserted-by":"crossref","first-page":"9608","DOI":"10.1073\/pnas.95.16.9608","article-title":"Single-nucleotide polymorphism in the human mu opioid receptor gene alters beta-endorphin binding and activity: possible implications for opiate addiction","volume":"95","author":"Bond","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.coph.2008.12.016_bib36","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/sj.mp.4001504","article-title":"Substantial attributable risk related to a functional mu-opioid receptor gene polymorphism in association with heroin addiction in central Sweden","volume":"9","author":"Bart","year":"2004","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.coph.2008.12.016_bib37","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1093\/hmg\/ddl024","article-title":"Association between two mu-opioid receptor gene (OPRM1) haplotype blocks and drug or alcohol dependence","volume":"15","author":"Zhang","year":"2006","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.coph.2008.12.016_bib38","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1097\/00008571-200412000-00002","article-title":"Redefinition of the human kappa opioid receptor gene (OPRK1) structure and association of haplotypes with opiate addiction","volume":"14","author":"Yuferov","year":"2004","journal-title":"Pharmacogenetics"},{"key":"10.1016\/j.coph.2008.12.016_bib39","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1002\/ajmg.b.30510","article-title":"Human kappa opioid receptor gene (OPRK1) polymorphism is associated with opiate addiction","volume":"144","author":"Gerra","year":"2007","journal-title":"Am J Med Genet B Neuropsychiatr Genet"},{"key":"10.1016\/j.coph.2008.12.016_bib40","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/sj.mp.4002035","article-title":"The OPRD1 and OPRK1 loci in alcohol or drug dependence: OPRD1 variation modulates substance dependence risk","volume":"13","author":"Zhang","year":"2008","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.coph.2008.12.016_bib41","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1002\/ajmg.10362","article-title":"Potentially functional polymorphism in the promoter region of prodynorphin gene may be associated with protection against cocaine dependence or abuse","volume":"114","author":"Chen","year":"2002","journal-title":"Am J Med Genet"},{"key":"10.1016\/j.coph.2008.12.016_bib42","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1002\/ajmg.b.30238","article-title":"Confirmation of the association between a polymorphism in the promoter region of the prodynorphin gene and cocaine dependence","volume":"139B","author":"Dahl","year":"2005","journal-title":"Am J Med Genet B Neuropsychiatr Genet"},{"key":"10.1016\/j.coph.2008.12.016_bib43","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1111\/j.1369-1600.2007.00069.x","article-title":"Prodynorphin gene promoter repeat associated with cocaine\/alcohol codependence","volume":"12","author":"Williams","year":"2007","journal-title":"Addict Biol"},{"key":"10.1016\/j.coph.2008.12.016_bib44","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1002\/ajmg.b.30531","article-title":"The opioid system in alcohol and drug dependence: family-based association study","volume":"144","author":"Xuei","year":"2007","journal-title":"Am J Med Genet B Neuropsychiatr Genet"},{"key":"10.1016\/j.coph.2008.12.016_bib45","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1097\/00041444-200512000-00010","article-title":"Association of a polymorphism in the Homer1 gene with cocaine dependence in an African American population","volume":"15","author":"Dahl","year":"2005","journal-title":"Psychiatr Genet"},{"key":"10.1016\/j.coph.2008.12.016_bib46","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1111\/j.1530-0277.2008.00663.x","article-title":"The tachykinin receptor 3 is associated with alcohol and cocaine dependence","volume":"32","author":"Foroud","year":"2008","journal-title":"Alcohol Clin Exp Res"},{"key":"10.1016\/j.coph.2008.12.016_bib47","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.neulet.2008.02.042","article-title":"Association of polymorphisms in the melanocortin receptor type 2 (MC2R, ACTH receptor) gene with heroin addiction","volume":"435","author":"Proudnikov","year":"2008","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.coph.2008.12.016_bib48","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1001\/archpsyc.61.6.597","article-title":"Association of specific haplotypes of D2 dopamine receptor gene with vulnerability to heroin dependence in 2 distinct populations","volume":"61","author":"Xu","year":"2004","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.coph.2008.12.016_bib49","first-page":"28","article-title":"Combined effect of promoter polymorphisms in the dopamine D4 receptor and the serotonin transporter genes in heroin dependence","volume":"7","author":"Szilagyi","year":"2005","journal-title":"Neuropsychopharmacol Hung"},{"key":"10.1016\/j.coph.2008.12.016_bib50","doi-asserted-by":"crossref","first-page":"4552","DOI":"10.1073\/pnas.0504789103","article-title":"A dopamine transporter gene functional variant associated with cocaine abuse in a Brazilian sample","volume":"103","author":"Guindalini","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.coph.2008.12.016_bib51","doi-asserted-by":"crossref","DOI":"10.1038\/npp.2008.126","article-title":"Association between the catechol-O-methyltransferase Val158Met polymorphism and cocaine dependence","author":"Lohoff","year":"2008","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.coph.2008.12.016_bib52","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1097\/01.fpc.0000182782.87932.d6","article-title":"Association analysis of polymorphisms in serotonin 1B receptor (HTR1B) gene with heroin addiction: a comparison of molecular and statistically estimated haplotypes","volume":"16","author":"Proudnikov","year":"2006","journal-title":"Pharmacogenet Genomics"},{"key":"10.1016\/j.coph.2008.12.016_bib53","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/ajmg.b.20111","article-title":"Association between low-activity serotonin transporter genotype and heroin dependence: behavioral and personality correlates","volume":"126B","author":"Gerra","year":"2004","journal-title":"Am J Med Genet B Neuropsychiatr Genet"},{"key":"10.1016\/j.coph.2008.12.016_bib54","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1007\/s10519-007-9187-7","article-title":"TPH2 and TPH1: association of variants and interactions with heroin addiction","volume":"38","author":"Nielsen","year":"2008","journal-title":"Behav Genet"},{"key":"10.1016\/j.coph.2008.12.016_bib55","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1002\/ajmg.b.30429","article-title":"Association analysis of GABA receptor subunit genes on 5q33 with heroin dependence in a Chinese male population","volume":"144","author":"Loh","year":"2007","journal-title":"Am J Med Genet B Neuropsychiatr Genet"},{"key":"10.1016\/j.coph.2008.12.016_bib56","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/sj.mp.4000247","article-title":"Cannabinoid receptor gene (CNR1): association with i.v. drug use","volume":"2","author":"Comings","year":"1997","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.coph.2008.12.016_bib57","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1038\/sj.mp.4001560","article-title":"Human cannabinoid receptor 1: 5\u2032 exons, candidate regulatory regions, polymorphisms, haplotypes and association with polysubstance abuse","volume":"9","author":"Zhang","year":"2004","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.coph.2008.12.016_bib58","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1038\/sj.tpj.6500352","article-title":"(AAT)n repeat in the cannabinoid receptor gene (CNR1): association with cocaine addiction in an African\u2013Caribbean population","volume":"6","author":"Ballon","year":"2006","journal-title":"Pharmacogenomics J"},{"key":"10.1016\/j.coph.2008.12.016_bib59","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.1093\/hmg\/ddi244","article-title":"CHRM2 gene predisposes to alcohol dependence, drug dependence and affective disorders: results from an extended case\u2013control structured association study","volume":"14","author":"Luo","year":"2005","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.coph.2008.12.016_bib60","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.molbrainres.2005.07.008","article-title":"Brain-derived neurotrophic factor (Val66Met) genetic polymorphism is associated with substance abuse in males","volume":"140","author":"Cheng","year":"2005","journal-title":"Brain Res Mol Brain Res"},{"key":"10.1016\/j.coph.2008.12.016_bib61","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1111\/j.1601-183X.2007.00314.x","article-title":"Association of the 54-nucleotide repeat polymorphism of hPer3 with heroin dependence in Han Chinese population","volume":"7","author":"Zou","year":"2007","journal-title":"Genes Brain Behav"},{"key":"10.1016\/j.coph.2008.12.016_bib62","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1093\/hmg\/ddl460","article-title":"Multiple ADH genes modulate risk for drug dependence in both African- and European-Americans","volume":"16","author":"Luo","year":"2007","journal-title":"Hum Mol Genet"}],"container-title":["Current Opinion in Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471489208002142?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471489208002142?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T06:47:18Z","timestamp":1761461238000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1471489208002142"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,2]]},"references-count":62,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,2]]}},"alternative-id":["S1471489208002142"],"URL":"https:\/\/doi.org\/10.1016\/j.coph.2008.12.016","relation":{},"ISSN":["1471-4892"],"issn-type":[{"value":"1471-4892","type":"print"}],"subject":[],"published":{"date-parts":[[2009,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Opiate and cocaine addiction: from bench to clinic and back to the bench","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coph.2008.12.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2009 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}